William Blair Has Negative Forecast for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at William Blair dropped their FY2024 earnings per share estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, November 13th. William Blair analyst S. Corwin now forecasts that the company will post earnings of ($2.00) per share for the year, down from their previous estimate of ($1.58). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share. William Blair also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.70) EPS.

Other research analysts also recently issued research reports about the company. JMP Securities initiated coverage on Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target for the company. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Guggenheim initiated coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Maxim Group increased their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Up 4.3 %

Shares of Zevra Therapeutics stock opened at $8.97 on Monday. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.21. The company has a market capitalization of $478.78 million, a PE ratio of -4.55 and a beta of 1.93. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The business has a 50-day moving average of $8.06 and a 200-day moving average of $6.54.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. During the same period in the previous year, the business posted ($0.40) earnings per share.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ZVRA. International Assets Investment Management LLC boosted its position in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares during the period. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics during the first quarter worth about $64,000. The Manufacturers Life Insurance Company increased its holdings in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after acquiring an additional 2,452 shares during the period. Hunter Associates Investment Management LLC acquired a new position in Zevra Therapeutics during the 3rd quarter valued at about $92,000. Finally, XTX Topco Ltd acquired a new position in shares of Zevra Therapeutics during the third quarter worth approximately $94,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.